Stefanie Milker-Zabel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stefanie Milker-Zabel has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Jürgen Debus
12 shared publicationsWolfgang Schlegel
9 shared publicationsAngelika Zabel-Du Bois
7 shared publicationsPeter Huber
7 shared publicationsMichael Wannenmacher
5 shared publicationsAngelika Zabel
4 shared publications
Latest Publications
- 1 June 2012
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 83 (2) , 525-532
Proposal for a New Prognostic Score for Linac-Based Radiosurgery in Cerebral Arteriovenous Malformations
- 1 June 2012
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 83 (2) , 525-532
Proposal for a New Prognostic Score for Linac-Based Radiosurgery in Cerebral Arteriovenous Malformations
- 13 December 2009
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 98 (3) , 367-372
Patterns of failure after stereotactic radiotherapy of intracranial meningioma
The aim of this work is to evaluate patterns of failure in patients with recurrent meningioma after stereotactic radiotherapy. Of 411 patients with intracranial meningioma treated with radiotherapy at our institution, 22 patients with local tumor progression diagnosed by magnetic resonance imaging (MRI) after radiotherapy (RT) were identified and further investigated. The histologic grade of the meningiomas was World Health Organization (WHO) grade I in 54.5%, WHO grade II in 27.3%, and WHO grade III in 9.1% of cases. Fourteen patients had received fractionated stereotactic RT; five patients underwent intensity-modulated RT. The median total dose was 57.6 Gy at 1.8 Gy/fraction, five times weekly. Local recurrences were divided into the dosimetric categories “central” (“in-field”) and “marginal” (“out-field”). Median follow-up was 59.5 months. Eleven local failures were found to be central, and 11 were marginal. Recurrence-free survival (P < 0.05) and site of local recurrence (P < 0.05) depended statistically significantly on histology. Median recurrence-free survival was 46 months for patients with benign meningioma (WHO grade I) and 31.5 months for patients with higher-grade meningioma (WHO grade II/III). In the WHO grade I group, three recurrences were central and nine were marginal, whereas in the WHO grade II/III group seven recurrences were central and one was marginal. Median time to local tumor progression and site of local recurrence significantly depended on histological grade of meningioma. Regarding site of failure, improvement of dose coverage for benign meningiomas and dose escalation for high-grade tumors might further improve therapy outcome.
- 13 December 2009
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 98 (3) , 367-372
Patterns of failure after stereotactic radiotherapy of intracranial meningioma
The aim of this work is to evaluate patterns of failure in patients with recurrent meningioma after stereotactic radiotherapy. Of 411 patients with intracranial meningioma treated with radiotherapy at our institution, 22 patients with local tumor progression diagnosed by magnetic resonance imaging (MRI) after radiotherapy (RT) were identified and further investigated. The histologic grade of the meningiomas was World Health Organization (WHO) grade I in 54.5%, WHO grade II in 27.3%, and WHO grade III in 9.1% of cases. Fourteen patients had received fractionated stereotactic RT; five patients underwent intensity-modulated RT. The median total dose was 57.6 Gy at 1.8 Gy/fraction, five times weekly. Local recurrences were divided into the dosimetric categories “central” (“in-field”) and “marginal” (“out-field”). Median follow-up was 59.5 months. Eleven local failures were found to be central, and 11 were marginal. Recurrence-free survival (P < 0.05) and site of local recurrence (P < 0.05) depended statistically significantly on histology. Median recurrence-free survival was 46 months for patients with benign meningioma (WHO grade I) and 31.5 months for patients with higher-grade meningioma (WHO grade II/III). In the WHO grade I group, three recurrences were central and nine were marginal, whereas in the WHO grade II/III group seven recurrences were central and one was marginal. Median time to local tumor progression and site of local recurrence significantly depended on histological grade of meningioma. Regarding site of failure, improvement of dose coverage for benign meningiomas and dose escalation for high-grade tumors might further improve therapy outcome.
- 1 April 2009
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 94 (3) , 419-424
Fractionated stereotactic radiation therapy in the management of primary optic nerve sheath meningiomas
We analysed our long-term results after fractionated stereotactic radiotherapy (FSRT) in patients with primary optic nerve sheath (pONSM) meningioma, as a rare subtype of meningiomas. Between 01/1995 and 12/2007, 32 patients with pONSM were treated with FSRT. Fifteen patients received radiotherapy as primary treatment, four after biopsy, and six patients after surgical resection. Seven patients were irradiated for recurrent disease. Seventeen lesions were histologically proven and determined as WHO grade I pONSM. Median target volume was 15.7 cc, median total dose 54.9 Gy. Twenty-nine patients showed clinical symptoms before radiotherapy like reduced vision, unilateral loss of vision, or an exophthalmia. Median follow-up was 4.5 years. Overall local tumor control was 100%. Twenty-six patients had stable disease based on CT/MRI, while 6/32 had a partial remission of tumor volume. 97% of our patients showed stable vision or an improvement of visual acuity. Eleven patients (38%) showed an improvement of pre-existing clinical symptoms like double vision, exophthalmia and visual acuity. Only one patient showed an impairment of vision with progressive concentric decreasing of the visual field on the side of the irradiated ONSM. These data demonstrate that FSRT is an effective and safe treatment modality for local control in patients with pONSM with minimal risk of significant late toxicity.
- 1 April 2009
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 94 (3) , 419-424
Fractionated stereotactic radiation therapy in the management of primary optic nerve sheath meningiomas
We analysed our long-term results after fractionated stereotactic radiotherapy (FSRT) in patients with primary optic nerve sheath (pONSM) meningioma, as a rare subtype of meningiomas. Between 01/1995 and 12/2007, 32 patients with pONSM were treated with FSRT. Fifteen patients received radiotherapy as primary treatment, four after biopsy, and six patients after surgical resection. Seven patients were irradiated for recurrent disease. Seventeen lesions were histologically proven and determined as WHO grade I pONSM. Median target volume was 15.7 cc, median total dose 54.9 Gy. Twenty-nine patients showed clinical symptoms before radiotherapy like reduced vision, unilateral loss of vision, or an exophthalmia. Median follow-up was 4.5 years. Overall local tumor control was 100%. Twenty-six patients had stable disease based on CT/MRI, while 6/32 had a partial remission of tumor volume. 97% of our patients showed stable vision or an improvement of visual acuity. Eleven patients (38%) showed an improvement of pre-existing clinical symptoms like double vision, exophthalmia and visual acuity. Only one patient showed an impairment of vision with progressive concentric decreasing of the visual field on the side of the irradiated ONSM. These data demonstrate that FSRT is an effective and safe treatment modality for local control in patients with pONSM with minimal risk of significant late toxicity.
- 1 March 2008
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 70 (4) , 1213-1218
SU11657 Enhances Radiosensitivity of Human Meningioma Cells
- 1 March 2008
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 70 (4) , 1213-1218
SU11657 Enhances Radiosensitivity of Human Meningioma Cells
- 1 November 2006
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 182 (11) , 635-640
Fractionated Stereotactic Radiation Therapy in the Management of Benign Cavernous Sinus Meningiomas
To analyze own long-term results with fractionated stereotactic radiotherapy (FSRT) in patients with benign meningiomas of the cavernous sinus and to review the literature on these rare lesions. 57 patients were treated with FSRT for benign meningiomas of the cavernous sinus between 01/1990 and 12/2003 at the authors’ institution. Histology was WHO grade I in 28/57 lesions, and undetermined in 29/57 lesions. 29 patients received radiotherapy as primary treatment, ten following surgery, and 18 patients were irradiated for recurrent disease. Median target volume was 35.2 cm3. Median total dose was 57.6 Gy with 1.8 Gy per fraction. 51/57 patients showed clinical symptoms before radiotherapy like reduced vision (n = 19), diplopia (n = 25), or trigeminal hyp-/dysesthesia (n = 17). Median follow-up period was 6.5 years. 50/57 patients were followed for > 36 months. Overall local tumor control was 100%. 39/57 patients had stable disease based on CT/MRI, while 18/57 had a partial remission of tumor volume. Overall survival for patients with WHO grade I meningiomas was 95.5% after 5 and 10 years. Two patients died 2.8 and 4.1 years after radiotherapy due to cardiac failure. In 11/57 patients, preexisting neurologic deficits improved. There was one patient with recurrent hyperlacrimation of one eye on the side of the irradiated meningioma. Three patients complained about subjective visual deterioration after FSRT without any objective findings in an ophthalmologic examination. No late toxicity RTOG ≥ °III was seen. These data demonstrate that FSRT is an effective and safe treatment modality for local control of benign cavernous sinus meningiomas with a minimal risk of significant late toxicity. Darstellung der Langzeitergebnisse nach fraktionierter stereotaktischer Strahlentherapie (FSRT) von benignen Sinus-cavernosus-Meningeomen und Literaturübersicht dieser seltenen Befunde. Zwischen 01/1990 und 12/2003 wurden 57 Patienten mittels FSRT an einem benignen Sinus-cavernosus-Meningeom in der Abteilung der Autoren behandelt. Histopathologisch entsprachen 28/57 Befunde WHO-Grad I, und 29/57 Befunde waren ausschließlich bildmorphologisch eindeutig als Meningeom diagnostiziert worden. 29 Patienten wurden primär, zehn postoperativ und 18 in einer Rezidivsituation bestrahlt. Die mediane Zielvolumengröße betrug 35,2 cm3. Die mediane applizierte Gesamtdosis betrug 57,6 Gy bei einer wöchentlichen Fraktionierung von 5 × 1,8 Gy. Initial zeigten 51/57 Patienten neurologische Symptome, wie Sehverschlechterung (n = 19), Doppelbilder (n = 25) oder Trigeminushyp-/-dysästhesie (n = 17). Die lokale Tumorkontrollrate betrug 100% nach einer medianen Nachbeobachtungszeit von 6,5 Jahren. Bei 50/57 Patienten war der Nachbeobachtungszeitraum > 36 Monate. 39 Meningeome zeigten eine Größenkonstanz im CT/MRT, 18 Befunde eine Größenreduktion. Das Gesamtüberleben betrug 95,5% nach 5 und 10 Jahren. Zwei Patienten verstarben 2,8 und 4,1 Jahre nach Strahlentherapie an kardialer Ursache. Bei 11/57 Patienten zeigte sich nach Strahlentherapie eine deutliche Besserung der vorbestehenden neurologischen Symptomatik. Ein Patient entwickelte im Verlauf rezidivierendes Augentränen auf der Seite des bestrahlten Meningeoms. Drei Patienten berichteten über rezidivierende subjektive Sehverschlechterung ohne ophthalmologisches Korrelat. Es traten keine Spättoxizitäten RTOG ≥ °III auf. Die FSRT ist sicher anwendbar und erreicht gute lokale Tumorkontrollraten bei geringem Risiko für radiogene Spätkomplikationen.
- 1 November 2006
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 182 (11) , 635-640
Fractionated Stereotactic Radiation Therapy in the Management of Benign Cavernous Sinus Meningiomas
To analyze own long-term results with fractionated stereotactic radiotherapy (FSRT) in patients with benign meningiomas of the cavernous sinus and to review the literature on these rare lesions. 57 patients were treated with FSRT for benign meningiomas of the cavernous sinus between 01/1990 and 12/2003 at the authors’ institution. Histology was WHO grade I in 28/57 lesions, and undetermined in 29/57 lesions. 29 patients received radiotherapy as primary treatment, ten following surgery, and 18 patients were irradiated for recurrent disease. Median target volume was 35.2 cm3. Median total dose was 57.6 Gy with 1.8 Gy per fraction. 51/57 patients showed clinical symptoms before radiotherapy like reduced vision (n = 19), diplopia (n = 25), or trigeminal hyp-/dysesthesia (n = 17). Median follow-up period was 6.5 years. 50/57 patients were followed for > 36 months. Overall local tumor control was 100%. 39/57 patients had stable disease based on CT/MRI, while 18/57 had a partial remission of tumor volume. Overall survival for patients with WHO grade I meningiomas was 95.5% after 5 and 10 years. Two patients died 2.8 and 4.1 years after radiotherapy due to cardiac failure. In 11/57 patients, preexisting neurologic deficits improved. There was one patient with recurrent hyperlacrimation of one eye on the side of the irradiated meningioma. Three patients complained about subjective visual deterioration after FSRT without any objective findings in an ophthalmologic examination. No late toxicity RTOG ≥ °III was seen. These data demonstrate that FSRT is an effective and safe treatment modality for local control of benign cavernous sinus meningiomas with a minimal risk of significant late toxicity. Darstellung der Langzeitergebnisse nach fraktionierter stereotaktischer Strahlentherapie (FSRT) von benignen Sinus-cavernosus-Meningeomen und Literaturübersicht dieser seltenen Befunde. Zwischen 01/1990 und 12/2003 wurden 57 Patienten mittels FSRT an einem benignen Sinus-cavernosus-Meningeom in der Abteilung der Autoren behandelt. Histopathologisch entsprachen 28/57 Befunde WHO-Grad I, und 29/57 Befunde waren ausschließlich bildmorphologisch eindeutig als Meningeom diagnostiziert worden. 29 Patienten wurden primär, zehn postoperativ und 18 in einer Rezidivsituation bestrahlt. Die mediane Zielvolumengröße betrug 35,2 cm3. Die mediane applizierte Gesamtdosis betrug 57,6 Gy bei einer wöchentlichen Fraktionierung von 5 × 1,8 Gy. Initial zeigten 51/57 Patienten neurologische Symptome, wie Sehverschlechterung (n = 19), Doppelbilder (n = 25) oder Trigeminushyp-/-dysästhesie (n = 17). Die lokale Tumorkontrollrate betrug 100% nach einer medianen Nachbeobachtungszeit von 6,5 Jahren. Bei 50/57 Patienten war der Nachbeobachtungszeitraum > 36 Monate. 39 Meningeome zeigten eine Größenkonstanz im CT/MRT, 18 Befunde eine Größenreduktion. Das Gesamtüberleben betrug 95,5% nach 5 und 10 Jahren. Zwei Patienten verstarben 2,8 und 4,1 Jahre nach Strahlentherapie an kardialer Ursache. Bei 11/57 Patienten zeigte sich nach Strahlentherapie eine deutliche Besserung der vorbestehenden neurologischen Symptomatik. Ein Patient entwickelte im Verlauf rezidivierendes Augentränen auf der Seite des bestrahlten Meningeoms. Drei Patienten berichteten über rezidivierende subjektive Sehverschlechterung ohne ophthalmologisches Korrelat. Es traten keine Spättoxizitäten RTOG ≥ °III auf. Die FSRT ist sicher anwendbar und erreicht gute lokale Tumorkontrollraten bei geringem Risiko für radiogene Spätkomplikationen.
- 1 January 2006
- Published by Springer Nature in American Journal of Cancer
- Vol. 5 (6) , 363-370
Radiosensitizers in Brain Cancer
- 1 January 2006
- Published by Springer Nature in American Journal of Cancer
- Vol. 5 (6) , 363-370
Radiosensitizers in Brain Cancer
- 1 July 2004
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 59 (4) , 1088-1096
Stereotactic conformal radiotherapy in patients with growth hormone–secreting pituitary adenoma
- 1 July 2004
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 59 (4) , 1088-1096
Stereotactic conformal radiotherapy in patients with growth hormone–secreting pituitary adenoma